Around 78% of people who are living with HIV take a daily pill to manage their infection. These drugs work by preventing the ...

ART iniitiation, managing comorbidities addressed for aging patients ...

A once-weekly HIV pill combining the antiretroviral drugs islatravir and lenacapavir is as effective as a widely used ...

In closing out the TDF/TAF litigation chapter, Gilead is simultaneously moving to a new era of HIV treatment altogether with ...

CRISPR therapy EBT-101 targeted HIV DNA inside living humans for the first time, showing strong safety results but failing to prevent viral rebound after ART stopped.

For adults with virologically suppressed HIV-1, once-weekly oral islatravir-lenacapavir (ISL/LEN) is noninferior to ...

GENEVA/JOHANNESBURG, 5 August 2026—An oral monthly pill to prevent HIV, alimatravir (also known as MK-8527), produced by Merck Sharp & Dohme (MSD), is currently undergoing promising phase three trials ...

Figure 2 from the PURPOSE-1 trial changed the world. Between gray and red bars representing the study’s background HIV incidence and the arms randomized to receive oral pre-exposure prophylaxis (PrEP) ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...

Aging with HIV comes with an increased risk of other health problems. Failing to get adequate care could undermine fighting the virus. (Story aired on Weekend Edition Saturday on June 15, 2024.) ...

Cambodia is the first country in the Asia–Pacific to reach the 95–95–95 targets. There is hope that other countries might ...

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...